Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EX02 CAR-T in Relapsed and Refractory Acute Myeloid Leukemia
NCT06642025Phase 1Recruiting
- Start
- Sep 2024
- Primary completion
- Aug 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EX02 in acute myeloid leukemia (AML). Primary endpoints: Treatment-Emergent Adverse Events at 3 months and Overall Response Rate at 60 days. Started Sep 2024; status: recruiting.
02
Drugs
EX02
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06642025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06642025.